scispace - formally typeset
Search or ask a question
Author

Susan J. Hartmann

Bio: Susan J. Hartmann is an academic researcher from G. D. Searle & Company. The author has contributed to research in topics: Benzopyran & Pyrazole. The author has an hindex of 4, co-authored 4 publications receiving 459 citations.

Papers
More filters
Patent
17 Nov 1999
TL;DR: A class of pyrazole derivatives described for use in treating p38 kinase mediated disorders are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
Abstract: A class of pyrazole derivatives described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.

182 citations

Patent
18 Apr 1998
TL;DR: A class of benzopyran derivatives for use in treating cyclooxygenase-2 mediated disorders was described in this article, where compounds of particular interest are defined by Formula (I'), wherein X, A?1, A2, A3, A4?, R, R', R?1 and R2? are as described in the specification.
Abstract: A class of benzopyran derivatives is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula (I'), wherein X, A?1, A2, A3, A4?, R, R', R?1 and R2? are as described in the specification.

148 citations

Patent
15 Oct 1999
TL;DR: In this article, a class of benzopyrans, benzothiopyrans and dihydroquinolines, dihydronaphthalenes, and analogs thereof, are described for use in treating cyclooxygenase-2 mediated disorders.
Abstract: A class of benzopyrans, benzothiopyrans, dihydroquinolines, dihydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula (I') wherein X, A?1, A2, A3, A4?, R, R'', R?1 and R2? are as described in the specification.

109 citations

Patent
18 Nov 1999
TL;DR: In this article, a novel process of preparing selected 5-substituted pyrazoles useful as p38 kinase and COX-2 inhibitors is described. But the process is not described.
Abstract: This invention relates to a novel process of preparing selected 5-substituted pyrazoles useful as p38 kinase and COX-2 inhibitors.

20 citations


Cited by
More filters
Patent
07 Nov 2005
TL;DR: In this article, a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity.
Abstract: The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf

341 citations

Patent
28 Mar 2002
TL;DR: In this paper, the authors provide a compound of formula I or II:or a pharmaceutically acceptable derivative thereof, wherein R1, R2, R3, and R4 are as described in the specification.
Abstract: The present invention provide a compound of formula I or II:or a pharmaceutically acceptable derivative thereof, wherein R1, R2, R3, and R4 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian proteinkinase involved cell proliferation, cell death and response to extracellular stimuli; and Src-family kinases, especially Src and Lck kinases. These compounds are also inhibitors of GSK3 and CDK2 kinases. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

293 citations

Patent
12 Apr 2000
TL;DR: In this paper, novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
Abstract: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

290 citations

Patent
27 Aug 1999
TL;DR: In this article, a method to inhibit TGF-β and/or p38-α kinase using compounds of formula (1) or the pharmaceutically acceptable salts thereof was proposed.
Abstract: The invention is directed to methods to inhibit TGF-β and/or p38-α kinase using compounds of formula (1) or the pharmaceutically acceptable salts thereof wherein R3 is a noninterfering substituent; each Z is CR2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar' is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.

272 citations

Patent
27 Jul 2007
TL;DR: In this article, the compounds of Formulae 1, 1A, 1B and 1C including all geometric and stereoisomers, N-oxides, and salts thereof are disclosed.
Abstract: Disclosed are compounds of Formulae 1, 1A, 1B and 1C including all geometric and stereoisomers, N-oxides, and salts thereof, wherein R1, R2, R4a1, R4a2, A, Aa, G, M, W, Z1, Z3, X, J, J1 and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

217 citations